9vHPV vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Adenocarcinoma in Situ, Condylomata Acuminata
Trial Timeline
Jun 29, 2018 → Jan 29, 2019
NCT ID
NCT03546842About 9vHPV vaccine
9vHPV vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03546842. Target conditions include Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05450705 | Phase 3 | Active |
| NCT05314023 | Phase 3 | Active |
| NCT05285826 | Phase 3 | Active |
| NCT04772534 | Phase 3 | Completed |
| NCT04708041 | Phase 3 | Active |
| NCT04199689 | Phase 3 | Active |
| NCT03546842 | Phase 3 | Completed |
| NCT01651949 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections